Investigation of blood mutations in elderly lymphoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate blood mutations in elderly patients diagnosed with B-cell Non-Hodgkin lymphoma who require systemic treatment. It focuses on patients aged 60 and older, examining the impact of chemotherapy on blood cell mutations and the associated risks of treatment side effects and mortality. Blood samples will be collected at various stages of treatment, and quality of life questionnaires will be administered electronically. The study seeks to identify which patients may benefit from traditional chemotherapy versus novel therapies with fewer side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of r/r B-cell Non-Hodgkin lymphoma
* In need of systemic treatment with second (2.) or higher line of active therapy for lymphoma
* 60 years of age or older (no age maximum)

Exclusion Criteria:

* Unable to give written consent
* Non-Danish citizens

Where it's running

• Dept. of Hematology, Rigshospitalet
  Copenhagen, Denmark Recruiting

Study contacts

• Principal investigator: Simon Husby, MD PhD — Copenhagen University Hospital, Rigshospitalet
• Study coordinator: Simon Husby, MD PhD
• Email: simon.husby.01@regionh.dkZZZZZZ
• Phone: +45 3545 6060

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of exercise training in lymphoma survivors

  This study is testing whether adding aerobic and resistance exercise to usual care can improve fitness and health for people who have survived lymphoma.

  Recruiting Norwegian School of Sport Sciences · Oslo and 1 other locations · NCT06270667

• Investigating the impact of clonal hematopoiesis on chemotherapy complications in lymphoma patients

  This study is trying to see if having a certain blood condition called CHIP makes older lymphoma patients more likely to have problems like low blood counts and infections while they are getting chemotherapy.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT04053439

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Me capegfilgrastim to help prevent neutropenia in advanced breast cancer patients on chemotherapy

  This real-world registry tests whether mecapegfilgrastim used with chemotherapy helps prevent low white blood cells in adults with advanced breast cancer.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07899099

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.